By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Inc. 

100 Tice Boulevard

Woodcliff Lake  New Jersey  07677  U.S.A.
Phone: 201-692-1100 Fax: 201-692-1804


SEARCH JOBS
Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.

For more information about Eisai, please visit www.eisai.com


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: Approximately 2,600
Symbol: ESALF.PK
 



Industry
Pharmaceutical






Company News
Eisai Inc. (ESALF.PK) To Host Scientific Day On June 29, 2016 In New York City 6/22/2016 8:26:05 AM
Eisai Inc. (ESALF.PK) Release: FYCOMPA (Perampanel) Oral Suspension Now Available As An Option For Patients With Epilepsy Who May Have Difficulty Swallowing Tablets Or Prefer Liquids 6/15/2016 10:58:19 AM
Eisai Inc. (ESALF.PK) And Lennox-Gastaut Syndrome (LGS) Foundation Convened Experts To #HackLGS 6/15/2016 10:55:55 AM
Eisai Inc. (ESALF.PK) Enters Into A Collaboration Agreement To Co-Promote LENVIMA (Lenvatinib) In Combination With Everolimus In The U.S. 6/3/2016 6:07:20 AM
AbbVie (ABBV) And Eisai Inc. (ESALF.PK) Subsidiary EA Pharma Commence Co-promotion Of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA In The Field Of Gastrointestinal Disease 6/1/2016 9:14:46 AM
FDA Approves Eisai Inc. (ESALF.PK)'s LENVIMA (Lenvatinib) For The Treatment Of Patients With Advanced Renal Cell Carcinoma In Combination With Everolimus Following Prior Anti-Angiogenic Therapy 5/16/2016 6:04:35 AM
Dr. Avinash Desai Appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group At Eisai Inc. (ESALF.PK) 4/20/2016 6:45:24 AM
Eisai Inc. (ESALF.PK) Release: Paul Hawthorne Appointed Senior Vice President, U.S. Commercial, Neurology Business Group At Eisai Inc. (ESALF.PK) 4/6/2016 6:29:27 AM
Data On Eisai Inc. (ESALF.PK)'s Halaven (eribulin mesylate) Injection In Advanced Liposarcoma Published In The Lancet 2/11/2016 6:31:52 AM
Eisai Inc. (ESALF.PK)'s Lenvatinib Receives FDA Priority Review For The Potential Treatment Of Advanced Renal Cell Carcinoma In Combination With Everolimus 1/18/2016 10:50:40 AM
12345678910...
//-->